Clinical Trials – Page 8 – media

Brain Studies Now Considered Clinical Trials by NIH

The NIH has amended its definition of clinical trials to include brain studies, introducing new regulations considered unnecessary by many researchers.
- Source: medicalnewsbulletin
- 682
- October 27, 2017
brain Clinical Trials NIH
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated.
- Source: Pfizer
- 701
- October 17, 2017
Clinical Trials inhibitor Phase tyrosine kinase
Ebola vaccines from GSK, Merck elicit yearlong response, study finds

After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end. But the investigators have now published results showing the shots from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination.
- Source: Fiercepharma
- 811
- October 16, 2017
aspirations Clinical Trials Ebola
Ardelyx’s Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Ardelyx, Inc. (ARDX) reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C). The study hit statistical significance for the primary endpoint and all secondary endpoints evaluated for the topline results and demonstrated the ability to normalize bowel movements.
- Source: finance.yahoo
- 564
- October 16, 2017
bowel syndrome Clinical Trials constipation
Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

Merck took a dominant position in frontline lung cancer with the approval of a combination of Keytruda and chemo. And it isn’t just waiting around to see if any combination of a PD-(L)1 with a CTLA4 can come along and knock it off its market-leading perch.
- Source: Endpts
- 624
- October 9, 2017
cancer Clinical Trials lung Phase
Pfizer launches upstart with $103M, phase 3-ready drugs

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.
- Source: Fiercebiotech
- 581
- September 27, 2017
Clinical Trials Pfizer Series
AbbVie Announces Positive Topline Results from Phase 3 MURANO study

AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA/VENCLYXTO (Venetoclax) Tablets in combination with Rituxan® (rituximab) met its primary endpoint.
- Source: news.abbvie
- 682
- September 20, 2017
Clinical Trials CLL Phase rituximab Venetoclax
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 563
- September 12, 2017
asthma Clinical Trials dupilumab Phase
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 750
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
- Source: news.open-medical
- 590
- September 6, 2017
BPDCN CAR–T Clinical Trials Company Insight CRS

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.